Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
J-ALTA
Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)
- NCT03410108 ↗
- Completed
- Takeda
- Focused
We haven't built an HCP commentary report on J-ALTA (brigatinib in ALK-positive advanced non-small cell lung cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on J-ALTA so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Single-Arm, Multicenter, Phase 2 Study of Brigatinib in Japanese Patients With ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
- Phase
- Phase 2
- Status
- Completed
- Conditions
- ALK-positive Advanced NSCLC
- Interventions
- Brigatinib
- Arms
- Brigatinib 90 mg + Brigatinib 180 mg · Experimental
- Enrollment
- 104
- Primary outcomes
- Confirmed Objective Response Rate (ORR) in the Main Cohort of the Refractory Expansion Part
- 12 Months Progression-Free Survival (PFS) Rate in the Tyrosine Kinase Inhibitor (TKI) Naïve Expansion Cohort
- Sponsor
- Takeda
- Start
- Jan 29, 2018
- Primary completion
- Sep 29, 2020
- Results posted
- Yes
- Registry record
- NCT03410108 · updated May 8, 2024
Publications
linked from the registry- Mok T, Nishio M, Yoshida T, Ahn MJ, Kudou K, Asato T, Yang H, Tong X, Vincent S, Zhang P, Yamamoto N, Kim ES. Efficacy and safety of brigatinib after alectinib in patients with ALK-positive NSCLC: Integrated analysis of the ALTA-2 and J-ALTA studies. Lung Cancer. 2025 Nov;209:108793. doi: 10.1016/j.lungcan.2025.108793. Epub 2025 Oct 9. PubMed 41110382
- Sugawara S, Kondo M, Yokoyama T, Kumagai T, Nishio M, Goto K, Nakagawa K, Seto T, Yamamoto N, Kudou K, Asato T, Zhang P, Ohe Y. Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study. Int J Clin Oncol. 2022 Dec;27(12):1828-1838. doi: 10.1007/s10147-022-02232-7. Epub 2022 Aug 29. PubMed 36036294